The history of the erectile dysfunction drug presents a intricate picture for those considering investment. While the initial release generated substantial gains, the lapse of its patent opened the door to off-brand versions, dramatically reducing sales. This creates a particular risk for firms banking on comparable blockbuster offerings, suggestin

The story of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, producing billions in sales , its patent expiration created a deluge of knock-off medications, significantly diminishing its dominance. While specific pharmaceutical companies may attempt to capitalize on similar condition